Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Deals

Vela Diagnostics Partners with SRL Inc. to Expand Molecular Diagnostics in Japan

Fineline Cube Oct 7, 2023

Singapore-based Vela Diagnostics, a global leader in integrated molecular solutions for diagnosing infectious diseases and...

Company Drug

Transcenta Secures FDA Approval for Phase III Trial of Osemitamab

Fineline Cube Oct 7, 2023

China-based Transcenta Holding Ltd (HKG: 6628) has announced that it has received approval from the...

Policy / Regulatory

Shanghai Boosts Community Healthcare with Enhanced Reimbursement and Services

Fineline Cube Sep 28, 2023

Shanghai’s healthcare security administration has announced a comprehensive set of measures aimed at enhancing community...

Company Deals

Novo Nordisk and Evotec Launch LAB eN² to Accelerate Drug Discovery for Rare Diseases

Fineline Cube Sep 28, 2023

Global healthcare company Novo Nordisk (NYSE: NVO) and drug discovery alliance Evotec (NASDAQ: EVO) have...

Company Deals

Roche Secures Global Rights to Ionis Pharmaceuticals’ Alzheimer’s and Huntington’s Disease Candidates

Fineline Cube Sep 28, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has announced the acquisition of global rights to develop,...

Company Drug

Takeda Receives FDA Approval for Subcutaneous Entyvio as UC Maintenance Therapy

Fineline Cube Sep 28, 2023

The US Food and Drug Administration (FDA) has granted Japan’s Takeda Pharmaceuticals (TYO: 4502) regulatory...

Company Medical Device

Neusoft Medical’s NeuRT Aurora Receives NMPA Approval for Advanced Radiotherapy Platform

Fineline Cube Sep 28, 2023

Neusoft Medical Systems Co., Ltd, a leading player in the medical technology sector, has announced...

Company Medical Device

CStone Pharmaceuticals’ PDGFRA Mutation Detection Kit Receives NMPA Approval

Fineline Cube Sep 28, 2023

CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has announced that it has received marketing...

Company Deals

RemeGen and Akeso Biopharma Initiate Phase II Study for Gastric Cancer Combo Therapy

Fineline Cube Sep 28, 2023

China-based RemeGen Ltd (HKG: 9995) is poised to conduct a Phase II clinical study in...

Company Drug

Eli Lilly’s Insulin Biosimilar YouBiAn Approved for Diabetes Treatment in China

Fineline Cube Sep 28, 2023

US pharmaceutical major Eli Lilly (NYSE: LLY) has announced that it has received market approval...

Company Drug

Everest Medicines’ Xerava Receives Marketing Approval from TFDA for cIAI Treatment

Fineline Cube Sep 28, 2023

Everest Medicines (HKG: 1952) has announced that it has received marketing approval for its antibiotic...

Company Medical Device

Sino Medical Sciences Receives Turkish Approval for HT Supreme Drug-Eluting Stent System

Fineline Cube Sep 28, 2023

Sino Medical Sciences Technology Inc., (SHA: 688108), a leading Chinese medical device company, has announced...

Company Drug

Konruns Pharmaceutical’s KC1036 Pediatric Indication Accepted for NMPA Review

Fineline Cube Sep 28, 2023

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced that the National Medical Products Administration...

Company Drug

Elpiscience Biopharmaceuticals Initiates Phase I Trial for Anti-LILRB2 Antibody ES009

Fineline Cube Sep 28, 2023

Elpiscience Biopharmaceuticals, a China-based biopharmaceutical company, has announced that the first patient has been dosed...

Company Deals

Triastek Inc. Secures $20.5 Million in Pre-Series C Financing for 3D Printing Pipeline

Fineline Cube Sep 28, 2023

China-based Triastek Inc., a company at the forefront of pharmaceutical-focused 3D printing, has reportedly secured...

Company Drug

Tasly Pharmaceuticals Gets NMPA Approval for B1344 Clinical Study in NASH

Fineline Cube Sep 28, 2023

Tasly Pharmaceuticals (SHA: 600535), a China-based pharmaceutical company, has announced that it has received approval...

Company Drug

ImmuneOnco Initiates Phase I Trial for CD24-Targeted Monoclonal Antibody IMM47

Fineline Cube Sep 28, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the first patient dosing in a...

Company Deals

MitrAssist Lifesciences Secures $100 Million in Series C Financing for Cardiovascular Devices

Fineline Cube Sep 28, 2023

MitrAssist Lifesciences Ltd, a Shanghai-based innovator in cardiovascular device manufacturing, has reportedly raised nearly USD...

Company Drug

Mabwell Bioscience Initiates Phase Ib/II Study for Nectin-4 Targeting ADC 9MW2821

Fineline Cube Sep 28, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced the first...

Company Drug

LEO Pharma Initiates Phase III Clinical Trial for Delgocitinib in China

Fineline Cube Sep 28, 2023

Denmark-based LEO Pharma A/S has announced the commencement of a China Phase III clinical study...

Posts pagination

1 … 519 520 521 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.